ECO ANIMAL HEALTH GROUP PLC

Board/Management Information • Aug 9, 2022

National Storage Mechanism | Additional information

RNS Number : 3220V

Eco Animal Health Group PLC

09 August 2022

9 August 2022

ECO Animal Health Group plc

(''ECO", the "Company" or the "ECO Group") (AIM: EAH)

Directorate Change

ECO Animal Health plc announces today that Tony Rawlinson, Non-Executive Director, has resigned from the Board to pursue other business opportunities, with immediate effect.

Andrew Jones the Chairman of ECO Animal Health commented:

"Tony has been a Non-Executive Director at ECO Animal Health plc for nearly eight years and has been involved in the development and implementation of important changes in corporate governance and remuneration policy.  The Board sincerely thanks him for his much-valued contribution and wish him well for the future."

For further information please contact:

ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)	020 8447 8899
IFC Advisory Graham Herring Zach Cohen	020 3934 6630
Singer Capital Markets (Nominated Adviser & Joint Broker) Mark Taylor George Tzimas	020 7496 3000
Investec (Joint Broker) Gary Clarence Brough Ransom Carlo Spingardi Peel Hunt LLP (Joint Broker) Dr Christopher Golden James Steel	020 7597 5970 020 7418 8900

Equity Development Hannah Crowe Matt Evans	020 7065 2692

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAUPUAPRUPPGMR